Clinical Trial Update: Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 trial testing belinostat and bortezomib in relapsed or refractory acute leukemias and myelodysplastic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelogenous Leukemia

Drugs mentioned

• BELEODAQ (BELINOSTAT)
• Velcade (bortezomib)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED